Implications of Stroke Risk Criteria on the Anticoagulation Decision in Nonvalvular Atrial Fibrillation
Alan S. Go(Kaiser Permanente), Daniel E. Singer(Massachusetts General Hospital), Lori Henault(Kaiser Permanente), Yuchiao Chang(Harvard University), Elaine M. Hylek(Boston University), Kathleen A. Phillips(Kaiser Permanente), Joe V. Selby(Kaiser Permanente), Leila H. Borowsky(Massachusetts General Hospital)
Cited by 200
Related Papers
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Prevalence of Diagnosed Atrial Fibrillation in Adults
|JAMA|2001|6.2k
Heart Disease and Stroke Statistics—2013 Update
|Circulation|2012|5.2k